[Gabapentin (Neurontin): a new possibility in the add-on therapy of partial epilepsies].
Gabapentin is a new antiepileptic drug for add-on therapy in patients above the age of 12 years with otherwise refractory partial seizures. Its unknown molecular mode of action is probably related to amino-acid-related binding sites in the brain. There are no hints to toxicologic effects or damage of the hematopoietic system, liver, or kidney in man. With the exception of a rather short elimination half life and dose-limited abortion, the pharmacokinetic data are very favourable. Due to lack of protein binding and metabolization, there are no major interactions with antiepileptic or other drugs. Efficacy has been demonstrated in three multicenter, placebo controlled trials involving a total of 705 patients. Secondarily generalized seizures seem to be the most likely to respond to 900 to 1800 mg/day, followed by complex partial and simple partial seizures. Tolerance is good, and serious side effects have not been observed up to now.
Krämer
G
G
Schweizerische Epilepsie-Klinik, Zürich.
D000085:Acetates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000588:Amines; D000927:Anticonvulsants / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids; D004828:Epilepsies, Partial / Q000188:drug therapy*; D000077206:Gabapentin; D006207:Half-Life; D006801:Humans; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin
Gabapentin (Neurontin): eine neue Möglichkeit der Add-on-Therapie partieller Epilepsien.